MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

A new pill for sleep apnea could offer hope for those struggling with CPAP machines, according to leading researchers. Trump demands voting changes hours after major Democrat wins CCTV footage shows ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, including liver disease, cancer and immunology. Gilead will stay on the lookout ...

“This strategy of [switching to bictegravir/emtricitabine/tenofovir alafenamide] is an appealing one for reducing severe interactions, toxicity and pill burden in ...

Bausch Health shareholders approved the adoption of a poison pill plan aimed at fending off a possible hostile bid. The pharmaceutical company said investors this week approved the shareholder rights ...

Culture of Life Services attorney Peter Breen argues before a three-judge panel at the Ninth Circuit Court of Appeals on Thursday, Oct. 9, in Pasadena, Calif. (Ninth Circuit Court of Appeals image via ...

The Food and Drug Administration is facing new pressure from lawmakers and anti-abortion groups, who are feeling betrayed after the agency approved a second generic version of the abortion drug ...

WASHINGTON -- Federal officials have approved another generic version of the abortion pill mifepristone, a regulatory formality that quickly triggered pushback from anti-abortion groups and ...

The abortion drug mifepristone will finally receive much-requested scrutiny by the Trump administration, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration ...

A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike ...